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Abstract
Background:  Hepatitis C is a serious problem on the Greek island of Crete, where a high
prevalence of antibodies against hepatitis C (anti-HCV) has recently been reported. This article
reports the findings of a study carried out in Crete, which investigated the prevalence of serum
autoantibodies in patients with chronic hepatitis C.
Patients and Methods:  One hundred and forty two patients (59 men and 83 women), who were
found anti-HCV seropositive in two hospitals and two Primary Health Care Centres in Crete, were
eligible. Sixty healthy blood donors (46 men, 14 women), which were negative to anti-HCV, were
u s e d  a s  t h e  c o n t r o l  g r o u p . T h e y  w e r e  r a n d o m l y  s e l e c t e d  f r o m  t h o s e  a t t e n d i n g  R e t h y m n o n
Hospital. Autoantibodies were identified using the indirect immunofluorescence (IFL) technique on
human epithelial cells from larynx cancer (HEp-2 cells), rat liver-kidney-stomach substrate (CT3)
and Chrithidia Luciliae (CL).
Results:  Serum autoantibodies were detected in 104 HCV patients, yielding an overall prevalence
of 73.2%. The most frequent autoantibodies were antinuclear antibodies (ANA), positive in 72
patients (50.7%). Anti-smooth muscle antibodies (ASMA) were detected in 33 patients (23.2%).
Only one patient was positive for LKM1 autoantibodies. No autoantibodies were found in 38
patients (26.7%). Autoantibodies were also found in 5 out of the 60 examined healthy blood donors
(8.3%).
Conclusions:  Autoantibodies, mainly ANA and ASMA are very common in HCV seropositive
patients from Crete. By contrast LKM1 autoantibodies are exceptionally rare in these patients.
Background
Hepatitis C, a serious health problem in Greece, is partic-
ularly common on the island of Crete, where a high prev-
alence of antibodies against hepatitis C (anti-HCV) has
recently been reported [1, 2, 3].
Previous studies have demonstrated that serum antinu-
clear (ANA) [4, 5, 6, 7, 8] and smooth muscle (ASMA) [9,
10, 11, 12, 13] antibodies are common in anti-HCV sub-
jects. In most cases ANA are of the speckled type and
ASMA exhibit the "vasal" (SMA-V) pattern. Moreover,
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LKM1, an autoantibody reacting with liver and kidney
microsomes, was also reported to be associated with
HCV chronic hepatitis [14, 15]. Unfortunately, similar
studies are not available in Greece.
The present study was therefore designed to establish the
prevalence of serum autoantibodies in HCV seropositive
patients in Crete. This article reports the findings in pa-
tients with chronic hepatitis C attending a number of pri-
mary and secondary health care units on the island.
Patients and methods
Patients
Patients who were found to be anti-HCV seropositive in
two Hospitals and two Primary Health Care Centres were
eligible. Criteria for selection were when the presence of
HCV RNA and an ALT elevation was above the formal
limits. The study group comprised of 142 patients (59
men and 83 women) from: (a) The University Hospital of
Heraklion (Department of Gastroenterology, 75 sub-
jects), (b) The General Hospital of Rethymnon (17 sub-
jects), (c) The Perama Health Centre (25 subjects) and
(d) The Spili Health Center (25 subjects). The University
Hospital was chosen because it is the Regional Reference
Centre for Hepatitis C. The General Hospital of Rethym-
non was chosen because it serves a county in which a very
high prevalence of hepatitis C has been reported [1, 3].
The Perama and Spili Health Centres are both primary
care units affiliated to Rethymnon Hospital and they
have participated in large epidemiological studies, previ-
ously reported [1, 2, 3,].
Patients included 83 women (58.5%) who had a median
age of 61 years (range: 27-96 years). A liver biopsy was
performed in 54 HCV seropositive (38%), Liver biopsy
was performed only on those patients who consented.
Histological sections were classified according to the
Ishak grading and staging system [16]. Forty-five of the
54 were classified as chronic Active Hepatitis (different
types), 6 classified as Cirrhosis, 2 as Primary Billary Cir-
rhosis, and one as Acute Viral Cholestatic Hepatitis. A
HCV RNA test was done by the Amplicore test (Roche Di-
agnostics) Genotyping was done by the Inno Lipa test
(Innogenetics, Belgium).
Sixty healthy blood donors negative for anti-HCV formed
the control group. They had been randomly selected
from those attending the Rethymnon Hospital. This
group consisted of 46 (76.7%) males and 14 (23.3%) fe-
males and had a median age of 35 years (range 20-55
years).
Serological tests
Serum from patients and controls was stored at -70° C af-
ter being tested for hepatitis C markers. Anti-HCV was
tested by the IMX Enzyme Immune Assay (Abbott Labo-
ratories). HCV RNA was identified by the Amplicor test
(Roche). The samples were examined at the Department
of Immunology of the General Hospital of Rethymnon
and autoantibodies were identified using the indirect im-
munofluorescence (IFL) technique on human epithelial
cells from larynx cancer (HEp-2 cells, Kallestad, USA),
rat liver-kidney-stomach (triple substrate - Kallestad-
USA/Byosystems-Spain) and the Crithidia Luciliae flag-
ellate (Kallestad-USA/Biosystems-Spain). The following
autoantibodies were determined: (a) by IFL on HEp-2
cells, antinuclear antibodies (ANA), antibodies against
Golgi Apparatus, Spindle Apparatus, Intermediate Fila-
ments (IMF) and Microfilaments (MF); (b) by IFL on
Crithidia L., antibodies to double-stranded DNA; (c) by
IFL on triple substrate, antibodies to mitochondria
(AMA), ribosomes, Liver-Kidney Microsomes (LKM1)
and Liver Cytosol, antibodies against Smooth Muscle
(ASMA), Parietal Cell Antibodies and Reticulin . The ini-
tial dilutions were: for ANA, Golgi Apparatus and Spin-
dle Apparatus 1:80; for ASMA, anti-Parietal Cell and
anti-Reticulin antibodies 1:40; for AMA, anti-ribosomes,
LKM1, anti-Liver Cytosol and anti-ds DNA 1:10. Positive
samples were diluted up to the highest positive titre.
Statistical analysis
The prevalence and the 95% confidence intervals were
estimated for serum antibodies. Confidence intervals for
the proportions were estimated using the normal ap-
proximation to the binomial distribution. The differenc-
es in prevalence were tested for statistical significance by
the Χ 2 test. Multivariable analysis by stepwise logistic re-
gression was also done.
Results
Patients' descriptives
Demographics of patients and controls are found in Ta-
ble 1. All anti-HCV positive subjects were also positive
for serum HCV RNA. Genotype 1 was identified in 65% of
patients.
Table 1: Demographics of HCV positive patients and healthy 
blood donors enrolled in the study.
HCV patients Healthy blood do-
nors
number (%) number (%)
Gender
Male 59 (41.5%) 46 (76.7%)
Female 83 (58.5%) 14 (23.3%)
Age group
27-44 years 15 (10.6%) 45 (75%)
45-64 years 63 (44.4%) 15 (25%)
> 64 years 64 (45.1%) --BMC Gastroenterology (2001) 1:4 http://www.biomedcentral.com/1471-230X/1/4
Prevalence of autoantibodies in HCV seropositive patients
As shown in Table 2, 104 HCV positive patients were
identified with serum autoantibodies, yielding an overall
prevalence of 73.2%. The most frequent autoantibodies
were ANA, positive in 72 patients (50.7%). ASMA were
detected in 33 patients (23.2%, 95% CI. 9-38%). No au-
toantibodies were found in 38 (95% CI. 36-62%) cases
(26.8%, 95% CI. 13-41%). Speckled immunofluorescence
of both coarse and fine type was the most frequent pat-
tern of ANA, accounting for 79% (57/72) ANA positive
cases. Homogeneous immunofluorescence was rare, oc-
curring in only 11% (8/72) ANA positive cases. Details of
ANA fluorescence are given in Table 3. Almost all (94% -
31/33) ASMA positive sera had the SMA-V pattern, the
remaining two cases exhibiting the SMA-T pattern. Only
one patient (0.7%) was LKM1 and ANA positive.
Of the minor reactivities, antibodies to gastric parietal
cells and anti-IMF were the most common, although at
low frequencies (14.1% and 9.1% respectively). Antibod-
ies to double-stranded DNA occurred in 4 patients
(2.8%), who were also all ANA positive and anti-MF in 2
cases (1.4%), both positive for ASMA with the SMA-T
pattern. One of these two was positive for homogeneous
ANA as well.
Prevalence of autoantibodies in healthy blood donors
Autoantibodies were found in 5 of the 60 (8.3%) healthy
blood donors who were examined. No autoantibodies
were detected in 55 cases (91.7%) (Table 2).Of the 5 au-
toantibody-positive controls, 4 had ANA of the speckled
type and one ASMA with tha SMA-V pattern. ANA, AS-
MA, antibodies to parietal cells and anti-IMF turned out
to be significantly more frequent in anti-HCV patients
than in healthy controls.
Multivariate analysis
None of the variables considered, including age, geno-
type, gender and histological staging, was significantly
associated with any autoantibody.
Discussion
This study confirms that the overall prevalence of serum
autoantibodies is high in HCV seropositive subjects. In
Table 2: Prevalence of serum autoantibodies in patients and controls from Crete, Greece.
HCV positive patients Healthy blood donors
Autoantibody (142) (60)
Titres Titres
n.% n. %
median median
ANA 72 50.7* 1:80 4 6.7* 1:80
ASMA 33 23.2* 1:160 1 1.7* 1:40
anti-gastric parietal cells 20 14.1* 1:40 0 -* -
anti-IMF 13 9.1* 1:40 0 -* -
anti-double stranded DNA 4 2.8 1:120 0 - -
anti-spindle apparatus 4 2.8 1:480 0 - -
anti-reticulin 3 2.1 1:160 0 - -
anti-MF 2 1.4 1:160 0 - -
anti-Golgi appartus 1 0.7 1:160 0 - -
AMA 1 0.7 1:640 0 - -
LKM1 10 .7 1 : 4 0 0 - -
* p < 0.01
Table 3: ANA patterns in 72 Greek patients with ANA positive 
HCV chronic hepatitis.
HCV positive patients HCV positive patients
ANA pattern (72) (72)
number %
coarse speckled 45 62.5
fine speckled 12 16.5
speckled all 57 79
homogeneous 8 11
speckled + nucleolar 4 5.5
centromere 2 2.8
membranous 1 1.4BMC Gastroenterology (2001) 1:4 http://www.biomedcentral.com/1471-230X/1/4
this respect, patients from Greece are substantially simi-
lar to those described in previous studies from other Eu-
ropean countries [4, 5, 8, 10, 11, 12, 13, 17].
Two distinct features, however, must be outlined: Greek
carriers of HCV infection are characterized by a low prev-
alence of LKM1 and a high prevalence of ANA. In this
study, LKM1 was detected in less than 1% of cases (only 1
patient was positive out of the 104 enrolled). Studies
from Italy have reported a 6% prevalence [4] raising as
high as 22% when children are considered [6]. The LKM1
prevalence in our Greek series is even lower than that re-
ported in other countries where LKM1 is only rarely
found such as Sweden [18] and the United States [7,19].
Moreover, in contrast these countries, autoimmune hep-
atitis is quite rare on Crete. From a group of more than
850 patients with chronic hepatitis, under observation
by the Department of Gastroenerology, only 3 cases of
autoimmune etiology could be identified, all with type 1
and none with type 2 autoimmune hepatitis (unpub-
lished observations). Therefore, in Crete, LKM1 antibod-
ies seem to be an exceptional finding in the setting of
both autoimmune and HCV-related chronic hepatitis.
The prevalence of ANA in our Greek series is definitely
higher than that reported by studies from other coun-
tries. The highest ANA rate so far published comes from
a Northern Italian study by Lenzi et al. [5] where ANA
occurred in 16% of cases and represented a more fre-
quent finding than ASMA. Such a figure however, is still
lower than that reported here (50.7%). Such a difference
could, in part, have two explanantions: 1. instead of the
traditional tissue sections, we have used the more sensi-
tive HEp-2 cells as IFL substrate for ANA screening. This
methodological approach could account for a higher
ANA prevalence, in spite of the different starting serum
dilution (1:80 rather than 1.40). 2. Greek patients are
older than those from other countries and certainly older
than the blood donor controls. They are thus more likely
to show autoimmune features including ANA. Further
studies are needed to shed light on this point.
Several concerns should also be discussed and those
mainly focused on our sampling procedures. Patients
and controls were not matched for age and sex. In most
series, patient selection was based on liver biopsy and
patients with chronic hepatitis were then selected. Only
54 of the 142 patients had liver biopsy. To explore if any
selection bias had been introduced, we performed a com-
parison of ANA and ASMA prevalence between those
which had liver biopsy and those which had not, with no
statistical difference being found. The prevalence of anti-
LKM1 only slightly changed by 2.4% when we considered
as a sample those patients who had liver biopsy.
In this study not only ANA and ASMA, which had already
been investigated, but other previously untested reactiv-
ities such as antibodies to parietal cells and IMF were
significantly more frequent in HCV patients than healthy
controls. The reason for such a high prevalence of differ-
ent autoantibodies during HCV infection is still a matter
of speculation. It has been suggested that the virus may
disrupt the immunological tolerance to various self-anti-
gens such as the cyp2D6 molecule which is the target of
LKM1 antibodies [8, 20, 21]. On the other hand, molecu-
lar mimicry may be involved [8, 20, 21]. A striking ho-
mology between E1 and NS regions of the HCV
polyprotein and cyp2D6 has been reported [22, 23].
Whether similar homologies exist between HCV-related
proteins and the molecular targets of such heterogene-
ous antibodies as ANA, ASMA, anti-parietal cells and
anti-IMF antibodies, remains to be clarified. The hy-
pothesis that viral genotypes may be critical for the de-
velopment of autoimmunity is inconsistent with the fact
that the occurrence of LKM1 antibodies is independent of
any particular HCV genotype [24].
The type of autoimmunity detected in our HCV patients
from Greece closely resembles that already reported
from other countries in the same setting: low-medium ti-
tre ANA and SMA mainly with the speckled and respec-
tively SMA-V pattern. This autoimmune status is distinct
from that marking type 1 autoimmune hepatitis and
characterized by high titre homogeneous ANA and/or
high titre actin-related ASMA mainly with the SMA-T
pattern. In particular, the concomitant positivity for both
the above reactivities has been claimed to be absolutely
specific for autoimmune hepatitis [17]. However, among
our HCV patients, one case was detected which exhibited
such an autoantibody status. A serological overlap be-
tween autoimmune and HCV-related chronic hepatitis
may occur, although to a minimal extent. Correct dis-
crimination between the two liver disorders is of para-
mount importance because of their quite distinct
therapeutic approach. However, in Crete, such a diag-
nostic problem is not as compelling as in other geograph-
ical areas due to the already mentioned rarity of
autoimmune hepatitis on the island.
Conclusions
In conclusion, serum autoantibodies, namely ANA and
ASMA, are frequently found in HCV seropositive sub-
jects from Crete. By contrast, LKM1 antibodies are virtu-
ally absent. General Practitioners and Hospital
Physicians in Crete should be aware that these antibod-
ies are more likely to be associated with HCV infection
than true autoimmune hepatitis.
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